Tumor Necrosis Factor-Alpha Inhibitor Use and Malignancy Risk: A Systematic Review and Patient Level Meta-Analysis.

Driscoll CB, Rich JM, Isaacson D, Nicolas J, Jiang Y, Mi X, Yang C, Kocsuta V, Goh R, Patel N, Li E, Siddiqui MR, Meyers T, Witte JS, Kachuri L, Zhang H, Beestrum M, Silberman P, Schaeffer EM, Kundu SD
Cancers · 2025 · doi:10.3390/cancers17030390 · PMID:39941759 · PMC11815771
OA: gold CC-BY-4.0
📄 Open PDF View on PubMed View at publisher

Abstract

Over the last two decades, tumor necrosis factor-alpha inhibitors (TNF-Is) have become standard therapies for chronic inflammatory disorders, with an ongoing expansion of indications and off-label applications [...].

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2025) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-10-11T09:27:45.537177+00:00
License: CC-BY-4.0 · commercial use OK · attribution required
Per Europe PMC